Aurobindo Pharma's CuraTeQ Terminates Biosimilar Deal with BioFactura

• Aurobindo Pharma's wholly-owned subsidiary, CuraTeQ Biologics, mutually terminated a license agreement with US-based BioFactura Inc.
• The agreement was for the commercialization of BFI-751, a proposed biosimilar of ustekinumab (Stelara).
• The decision was made after a strategic review, aligning with CuraTeQ's portfolio prioritization strategy.
• The termination is effective December 27, 2025, and is not expected to significantly impact Aurobindo's broader biosimilar strategy.
• The original deal, signed in July 2023, involved BioFactura receiving license fees and CuraTeQ having global manufacturing rights.

Why It Matters: Aurobindo Pharma's subsidiary ends a key biosimilar deal, citing strategic portfolio review.